Epithalon Research Peptide 2026 — Molecular Profile, Telomerase Pathway & Verification

Epithalon — also written epitalon or epithalone, and abbreviated AEDG for its four-residue sequence — is one of the most-studied compounds in telomere-biology and geroprotection research. It is a synthetic tetrapeptide derived from the amino-acid composition of epithalamin, a peptide preparation originally isolated from the pineal gland. For laboratories modeling telomerase regulation, cellular replicative capacity, and pineal-axis signaling, epithalon has become a standard reference peptide because it is small, chemically well-defined, and associated with a discrete, repeatedly investigated molecular endpoint: induction of telomerase activity in telomerase-negative human cells in vitro.

This guide is written for qualified laboratory researchers sourcing epithalon as a research compound. It covers the molecular profile, the mechanism at the pathway and enzyme level as described in the published literature, representative preclinical and in-vitro research data, real citations you can verify yourself through PubMed, and how to evaluate the analytical documentation that should accompany a peptide of this class. It also notes the current U.S. regulatory context, because epithalon is one of the compounds on the FDA’s July 2026 review docket.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

Epithalon is a compact linear tetrapeptide, which makes its analytical characterization straightforward relative to larger peptides.

• Compound name: Epithalon (also epitalon, epithalone; sequence abbreviation AEDG)
• CAS number: 307297-39-8
• Molecular formula: C₁₄H₂₂N₄O₉
• Molecular weight: ≈ 390.35 g/mol
• Sequence: Ala-Glu-Asp-Gly (H-Ala-Glu-Asp-Gly-OH)
• PubChem CID: 219042
• Class: Synthetic pineal-derived tetrapeptide (Khavinson peptide bioregulator)
• Appearance: White lyophilized or crystalline anhydrous powder; water-soluble

Epithalon was designed by the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic representation of the shortest bioactive fragment attributed to epithalamin, the bovine pineal extract studied by the same group. Its four-residue length and free-acid termini give it a distinct, low molecular weight that separates cleanly on reversed-phase HPLC and produces a single, unambiguous protonated-molecule signal near 391 Da on positive-mode LC-MS. That analytical simplicity is one reason epithalon is a useful method-development standard: a genuine sample should present as one dominant peak of the correct mass, and deviations are easy to spot.

Because the sequence contains two acidic residues (Glu and Asp), epithalon is anionic at neutral pH, which is relevant to chromatographic method selection and to distinguishing it from basic peptides during identity confirmation.

Section 2 — Mechanism (Pathway Language)

Epithalon is studied primarily for its interaction with the telomerase system and with pineal-axis gene-regulatory pathways. The published mechanistic literature describes it at the enzyme and gene-expression level, not at the level of any clinical endpoint.

The telomerase pathway. Telomerase is the ribonucleoprotein enzyme that adds TTAGGG repeats to chromosome ends, offsetting the telomere shortening that accompanies somatic cell division. Its catalytic subunit is TERT (telomerase reverse transcriptase). In the epithalon literature, the compound is studied for its capacity to induce TERT expression and telomerase enzymatic activity in cell types that are normally telomerase-negative, with telomere elongation reported as the downstream molecular readout. The most recent in-vitro work also describes an alternative route in certain lines — alternative lengthening of telomeres (ALT), a recombination-based, telomerase-independent pathway — indicating the endpoint (telomere length) can be reached through more than one mechanism depending on the cell system.

Pineal-axis and gene-regulatory signaling. Beyond telomerase, epithalon belongs to the “peptide bioregulator” class hypothesized to interact with regulatory regions of DNA and to modulate the expression of specific genes, including those associated with circadian and melatonin-related signaling in pineal tissue. In-silico and spectroscopic studies summarized in the 2025 review literature describe short peptides of this type as potential small-groove DNA-binding ligands, offering a proposed structural rationale for gene-expression effects. This remains an area of active mechanistic investigation rather than settled consensus.

In accordance with research-context framing, this article describes epithalon strictly at the enzyme, pathway, and gene-expression level. It is studied for its interaction with telomerase and pineal-axis signaling in controlled systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical & In-Vitro Research Data

The epithalon literature spans human cell culture, rodent models, and, more recently, independent Western replication.

In-vitro telomerase induction. The foundational cell-culture finding is that adding epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, restored measurable telomerase enzymatic activity, and produced telomere elongation. This is the single most-cited in-vitro result for the compound, and it framed epithalon as a candidate telomerase-inducing peptide for cell-longevity research. Related work from the same program reported that peptide treatment allowed human somatic cell cultures to exceed their normal division limit — an in-vitro replicative-capacity endpoint.

Recent independent replication (2025). A 2025 study published in Biogerontology re-examined epithalon across multiple human cell lines and reported increased telomere length, attributing the effect to telomerase upregulation in some lines and to ALT activity in others. Independent replication of this kind is significant because much of the earlier data originated from a single research group; the 2025 work broadens the evidentiary base while also refining the mechanistic picture.

Rodent geroprotection models. In preclinical animal work, epithalon (and the parent epithalamin preparation) has been studied in aging-biomarker and tumor-incidence models. In female Swiss-derived SHR mice given the peptide subcutaneously, published results reported a decreased frequency of chromosome aberrations in bone-marrow cells and effects on age-related estrous-function markers, alongside an increase in the lifespan of the longest-surviving cohort fraction relative to controls, without change in mean lifespan. Companion studies in other mouse strains reported reduced spontaneous tumor incidence. These are preclinical, animal-model findings; they characterize the compound’s behavior in controlled research systems and do not constitute evidence of any human outcome.

Across these studies, the recurring experimental thread is a measurable molecular endpoint — TERT expression, telomerase activity, telomere length, or chromosomal-aberration frequency — quantified in a defined cell or animal system. None of this data supports human-use conclusions.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed and PubMed Central (PMC). Researchers are encouraged to read the primary sources directly.

• Khavinson VK, Bondarev IE, Butyugov AA. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bull Exp Biol Med. 2003;135(6):590–592. PubMed: 12937682 — the foundational in-vitro telomerase-induction paper.
• Khavinson VK, et al. “Peptide promotes overcoming of the division limit in human somatic cell.” Bull Exp Biol Med. 2004. — in-vitro replicative-capacity endpoint.
• Anisimov VN, Khavinson VK, et al. “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.” Biogerontology. 2003. PubMed: 14501183 — preclinical rodent aging-biomarker and tumor-incidence study.
• Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. “Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties.” Int J Mol Sci. 2025;26(6):2691. PubMed: 40141333; PMC11943447 — recent comprehensive review of the in-vitro, in-vivo, and in-silico literature.
• “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Biogerontology. 2025. PMC12411320; DOI 10.1007/s10522-025-10315-x — 2025 independent multi-cell-line replication.

Citing real primary literature is a core part of the PYXAX research-context standard. Any source — vendor or publication — that references “studies” without traceable identifiers should be treated with caution. Note also that a substantial fraction of the earlier epithalon literature originates from a single research program; the strongest evidentiary practice is to weigh the independently replicated in-vitro findings most heavily.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, epithalon is used as a reference compound in several categories of in-vitro and preclinical work:

• Telomerase-induction assays — as a reference peptide in TRAP (telomere repeat amplification protocol) and TERT-expression assays in telomerase-negative cell lines.
• Telomere-length studies — as a comparator in qPCR-based or Southern-blot terminal-restriction-fragment measurements of telomere dynamics across serial passages.
• Replicative-senescence models — as a test agent in fibroblast and epithelial cell systems studying Hayflick-limit and population-doubling endpoints.
• Pineal-axis and gene-expression research — as a probe compound in studies of melatonin-related and circadian gene regulation in pineal-derived tissue models.
• Analytical method development — as a small, well-defined anionic tetrapeptide standard for validating reversed-phase HPLC and LC-MS identity methods.

Each of these applications is an in-vitro or preclinical research use. Compounds supplied for research are not intended for, and must not be used in, any human or veterinary context.

Section 6 — How to Evaluate a Source

Epithalon’s low molecular weight makes it easy to characterize correctly — and therefore easy to catch when documentation is inadequate. The following steps separate verifiable sourcing from marketing claims.

Step 1 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO 17025-accredited facility or equivalent recognized accreditation.

Step 2 — Confirm identity by mass spectrometry. A genuine epithalon sample should present a protonated-molecule signal consistent with a ~390.35 g/mol tetrapeptide on LC-MS. Because the molecule is small, mass confirmation is unambiguous; a COA that reports only “purity” without an identity mass is incomplete.

Step 3 — Confirm chromatographic purity. HPLC should show a single dominant peak. For a peptide this short, common impurities include deletion sequences and truncated fragments, which a well-resolved method will separate.

Step 4 — Verify lot specificity. The batch number on the COA must match the vial label, and the COA date should correspond to the production lot — not a single historical testing event applied across an entire catalog.

Step 5 — Check independent verification and a complete panel. A COA you can verify without contacting the vendor — through a QR-linked laboratory portal or a searchable community database — is independent. For cell-based telomerase work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound sensitive assay systems.

Section 7 — Regulatory Context (July 2026)

Researchers sourcing epithalon in the United States should be aware of the current compounding-review landscape. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review seven peptides — including epithalon — for potential inclusion on the Section 503A Bulk Drug Substances List. In its briefing documents posted in early July 2026, the FDA proposed that the committee not add these compounds to the list, citing incomplete characterization and limited human data. PCAC recommendations are advisory. This process concerns compounding-pharmacy permissions only; it does not change the status of epithalon as a compound supplied strictly for laboratory research. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX peptide-compliance landscape guide for the full regulatory picture.)

Section 8 — PYXAX Verification Standard

PYXAX supplies epithalon as a lyophilized research compound independently verified by accredited independent laboratories (ISO 17025) before listing.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP 85 LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number. The batch number on the vial matches the batch number on the COA in the PYXAX COA Library, so researchers can confirm identity before ordering.

Community verification. Select lots are submitted to Janoshik Analytical for community verification, with results publicly searchable by batch number — no vendor contact required.

Founding batch transparency. Initial founding batches were verified by Krause Analytical (accredited US laboratory). Ongoing production lots are tested across a network of accredited independent laboratories — including ILS Labs, Krause Analytical, and Janoshik — with a batch-specific COA published for every lot.

View PYXAX Epithalon →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/coa-library/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.